‌

US Patent 10898598 Triazine based radiopharmaceuticals and radioimaging agents

Patent 10898598 was granted and assigned to Molecular Insight Pharmaceuticals, Inc. on January, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

‌

Molecular Insight Pharmaceuticals, Inc.

Current Assignee

‌

Molecular Insight Pharmaceuticals, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

108985980

Patent Inventor Names

John W. Babich0

Craig Zimmerman0

Genliang Lu0

John L. Joyal0

Date of Patent

January 26, 2021

Patent Application Number

162311530

Date Filed

December 21, 2018

Patent Citations

‌

US Patent 10086096 Triazine based radiopharmaceuticals and radioimaging agents

‌

US Patent 10201624 Triazine based radiopharmaceuticals and radioimaging agents

Patent Citations Received

‌

US Patent 11712485 Triazine based radiopharmaceuticals and radioimaging agents

Patent Primary Examiner

‌

D. L. Jones

Patent abstract

Metal complexes including a radionuclide and a compound of Formula I and Formula II are potent inhibitors of PSMA.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10898598 Triazine based radiopharmaceuticals and radioimaging agents

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API